← Back to Search

Radiation Therapy

Device, HIFU for Prostate Cancer (SetPace Trial)

N/A
Waitlist Available
Led By Mark Schoenberg, M.D.
Research Sponsored by SonaCare Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

SetPace Trial Summary

This study will compare high intensity focused ultrasound to standard brachytherapy in the treatment of primary, organ confined prostate cancer.

Eligible Conditions
  • Prostate Cancer

SetPace Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months.

SetPace Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Device, HIFUExperimental Treatment1 Intervention
High Intensity Focused Ultrasound
Group II: Device, brachytherapyActive Control1 Intervention
Brachytherapy

Find a Location

Who is running the clinical trial?

SonaCare MedicalLead Sponsor
6 Previous Clinical Trials
211 Total Patients Enrolled
2 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer
Mark Schoenberg, M.D.Principal InvestigatorJohns Hopkins Medical Institution

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Washington
How old are they?
18 - 65
What site did they apply to?
HIFU Site: Urology of San Antonio
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer
2007. "Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00770822.
All > Prostate
~26 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top